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Summary Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients
were analysed with respect to TNM stage, histological type and carcinoembryonic antigen (CEA), CA125
antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were
closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had
the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent
prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually
complementary. We conclude that CA125 and CEA complement TNM classification and histological type for
the purpose of quantifying risk of death or recurrence.
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The tumour-node-metastasis (TNM) classification system is
the cornerstone for planning therapy options in patients with
non-small-cell lung cancer (NSCLC) (Bains, 1991). Such
staging of tumour spread is the best available prognostic
factor. However, its predictive power is limited. Differences
may be seen between expected and actual outcome after
curative resection among patients within the same TNM
category of risk. Efforts are under way to confirm the
possibility that long-term results or response to treatment
may be partially based on biological characteristics inherent
in tumour cells (Carney, 1991). Methods for the description
of biological tumour aggressiveness are rapidly expanding
(Carney, 1991; Lee and Hong, 1992).
Owing to their low sensitivity and specificity, tumour
markers have, until now, played a less important role in the
diagnosis and management ofNSCLC than has been the case
with most other common cancers (Bergman et al., 1993;
Strauss and Skarin, 1994; Jarvisalo et al., 1993). Nevertheless,
tumour markers might have a wide range of potential
applications within the field of NSCLC as tools for
description of tumour biological aggressiveness. Of these
tumour markers, carcinoembryonic antigen (CEA) and
squamous cell carcinoma antigen (SCC) have been two of
the most commonly used to date. Their sensitivity for
detecting the primary tumour is low, ranging from 30% to
60% (Strauss and Skarin, 1994) depending upon histological
type and TNM stage. Several authors have reported that
serum CEA and serum SCC assay provide useful information
for establishing preoperative prognosis in patients with
localised and resectable disease (Gail et al., 1984; Sanchez
et al., 1994), guiding follow-up after surgical treatment (Diez
et al., 1995) and monitoring response to chemotherapy in
advanced disease (Shinkai et al., 1986; Spiridonis et al., 1995).
CA125 was initially described as an ovarian cancer-associated
antigen, and has recently been assayed in NSCLC. In a
previous study we reported that serum levels of CA125
provide independent information on survival and tumour
relapse in patients undergoing curative surgical treatment for
NSCLC (Diez et al., 1994a).
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Analysis of tumour marker expression in NSCLC tumour
tissue has not been reported as frequently. In a previous
study we observed that cytosolic concentration of CEA, SCC
and CA125 is a particular and distinctive characteristic of
each histological type, something which could aid patholo-
gical classification (Picardo et al., 1994). In addition, high
CEA plus high CA125 content allows for identification of the
large-cell carcinoma histological subtype (Picardo et al.,
1994). In our opinion, this kind of study could lead to a
better understanding of the relationship between tumour
marker and the biological features of the neoplasm.
This study aimed at assessing the ability of preoperative
serum and cytosolic levels of CEA, CA125 and SCC antigens
to provide information on the risk of death and recurrence in
patients who had undergone curative surgical treatment for
NSCLC.
Patients and methods
Population
A total of 108 histologically proven NSCLC patients (99 men
and nine women; mean age 61 years) (s.d. 9 years) who
underwent curative resection of the tumour between October
1989 and October 1993 were included in the study. They were
consecutively submitted to our unit for surgical treatment.
Patients undergoing chemotherapy or radiation therapy
before surgery were not included. Careful, complete
sampling of mediastinal lymph node groups was performed
routinely before resection of the primary lesion. Patients who
died of complications after surgery during this period
(operative death) were not included. Histopathological
diagnosis was carried out in accordance with the WHO
classification of lung tumours (World Health Organization,
1981): 71 patients (65.7%) had squamous carcinoma, 29
(27%) adenocarcinoma and eight (7.3%), large-cell carcino-
ma. TNM staging (Mountain, 1986) was performed by
correlating the operative and histological findings: 55
patients (51%) were in stage I, 12 (11%) in stage II and 41
(38%) in IIIA. Follow-up was conducted prospectively.
During this period, two patients died as a result of unrelated
causes, 3 and 16 months after surgery respectively. Two
patients were lost to follow-up. Tumour recurrence was
diagnosed in 51 patients, 45 of whom have since died.
Median survival time of patients still living stands at 25
months (range 10-55).Specimens analysed and tumour marker assay
Serum and lung samples were obtained from all these
patients. Serum was obtained preoperatively. One sample
from the lung tumour was always obtained at the time of
Table I Distribution of the three markers in cytosol and serum
Markers in cytosol Markers in serum
CEA
Mean (s.d.) 417.0 (1762.7) 26.5 (97.2)
Median (ID) 61.1 (14.0- 140.0) 3.1 (2.2-8.0)
Range 0.1 -4730 0.1-874
CA125
Mean (s.d.) 136.5 (596.4) 25.5 (95.2)
Median (ID) 20.0 (4.8-69.0) 9.5 (2.2-20.0)
Range 0.1-6006 0.1 -968
SCC
Mean (s.d.) 44.4 (61.2) 3.2 (6.4)
Median (ID) 19.0 (4.0-55.0) 1.6 (0.5-3.4)
Range 0.1-346 0.0-48
s.d., standard deviation. ID, interquartile distance.
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surgery. The excised lung specimens were divided, one piece
being sent for histological examination and the other for
tumour marker assay. This specimen was cleaned of any
necrotic tissue, washed with ice-cold saline and immediately
frozen in liquid nitrogen. Total time elapsed from removal of
specimen to freezing was less than 15 min. Cytosols were
analysed immediately or stored at -80°C until assayed.
Separation and processing of cytosols was effected by a
previously described method (Picardo et al., 1994). Commer-
cially available kits were used and applied according to the
manufacturer's instructions: enzyme immunoassay for CEA
and CA125 (Hoffmann LaRoche, Basle, Switzerland), radio-
immunoassay for SCC (Abbott Laboratories, Wiesbaden-
Delkenheim, Germany). Cytosol protein concentration was
determined by the Lowry method. Results of CA125 in
cytosol are shown as U mg-1 of proteins. Results of CEA
and SCC in cytosol are shown as ng mg- of proteins.
Performance characteristics of immunometric assays
depend upon the matrix of the sample. Commercially
available kits are standardised for serum. As a prior step,
we therefore had to validate the technique for the cytosol
matrix. In order to ascertain the precision and accuracy of
the assay, the first ten lung cancer samples were divided into
four parts. All the steps of the analysis were repeated in these
Table II Predictors of survival in non-small cell lung cancer according to the univariate analysis.
Survival (months)
Variable No. ofpatients No. ofevents 12 24 36 Hazard ratio 95%CI P-value
Histological type
Squamous
Adenocarcinoma
Large-cell carcinoma
TNM stage
I
II
IIIA
71
29
8
55
12
41
29
10
6
18
5
22
87
86
38
94
83
67
66
66
25
73
75
43
44
54
25
51
54
33
0.84
3.44
1.14
2.41
0.41-1.73 0.642
1.41 -8.38 0.007
0.42-3.07 0.799
1.29-4.50 0.006
82 65 45
100 44 44
88 72
75 47
53
34
1.21
1.72
0.48-3.06 0.695
0.96-3.09 0.069
CEA in cytosol
<61.1 ng mg-
)61.1 ng mg-
CA125 in cytosol
<20 U mg-1
)20 U mg-1
SCC in cytosol
< 19 ng mg
>19 ng mg-1
CEA in serum
<5 ng ml-'
>5 ng ml-'
CA125 in serum
< 15 U ml-1
>15 U ml-1
SCC in serum
< 1.5 ng ml-1
> 1.5 ng ml-'
54
54
54
54
54
54
70
38
68
40
53
55
19
26
14
31
19
26
26
19
25
20
25
20
89 70 49 1
77 56 42 1.52
96 79 60
69 46 32 2.92
85 67 55 1
81 57 35 1.54
85 63 53
78 62 33
88 68 54
74 53 29
83 62 40
83 63 51
1.45
1.92
0.79
0.84-2.75 0.167
1.55-5.50 <0.001
0.85-2.78 0.155
0.80-2.61 0.221
1.06-3.47 0.031
0.44- 1.42 0.427
95% CI, 95% confidence interval.
Sex
Male
Female
99
9
Age
<65
) 65
40
5
23
22
65
37Serum and cytosolic CEA, CA125, SCC
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Figure 1 Cumulative probability of survival by TNM stages and
cytosolic concentration of CA125. Patients with tumour marker
level lower than the cut-off ( ), patients with levels higher than
the cut-off (- - - -). (a) Comparison in stages I-II: log-rank
P=0.013. (b) Comparison in stage Illa: log-rank P=0.020.
specimens separately. Variation coefficients of the technique
for cytosols were 15% for CEA, 13% for CA125 and 16%
for SCC. Intra-assay variation coefficients were 7% in the
CEA assay, 6% in CA125 and 8% in SCC. Interassay
variation coefficients were 10% in the CEA assay, 9% in
CA125 and 11% in SCC.
Statistical analysis
In the statistical analysis, median and interquartile distances
were used as summary measures, owing to the asymmetric
distribution of marker values. Survival and recurrence rates
linked to tumour marker levels were studied using the
Kaplan-Meier method, and differences between subgroups
of patients were compared using Mantel's log-rank test.
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Figure 2 Cumulative probability of survival in patients with
squamous carcinoma and adenocarcinoma categorised by
cytosolic concentration of CA125. Patients with tumour marker
level lower than the cut-off ( ), patients with levels higher than
the cut-off (-- - -). (a) Comparison in squamous carcinoma: log-
rank P<0.001. (b) Comparison in adenocarcinoma: log-rank
P=0.233.
Survival and disease-free survival were calculated from
surgery to last contact or death and from surgery to
recurrence respectively. Patients lost to follow-up and deaths
due to a different cause were considered as censored. The
importance of all prognostic factors considered for both
survival and recurrence was estimated using Cox's propor-
tional hazards regression model. The crude effect of each
predictor was evaluated, using unadjusted hazard ratios as an
estimate of relative risk. Possible interactions between tumour
markers and the other predictors were tested. In the
univariate study of survival, the tumour markers were
analysed as dichotomous variables. The following cut-offs
were used for serum: CEA, 5 ng ml-'; CA125, 15 U ml-';
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SCC, 1.5 ng ml-'. These values had been selected in a
previous study by our group by studying the receiver
operating characteristic curves (Diez et al., 1994a,b). No
generally accepted values exist as cut-offs for cytosol, and we
therefore decided to use the median value. In the absence of
any other reference, this has the advantage of furnishing a
balanced distribution of the sample. Accordingly, the cut-offs
for cytosol were: CEA, 61.1 ng mg-1; CA125, 20 U mg-1;
SCC, 19 ng mg-'. Sample size was not pre-established, but
was mainly determined by population incidence and thus by
the number of patients attending our hospital.
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Figure 3 Cumulative probability of survival in patients with
squamous carcinoma and adenocarcinoma categorised by serum
concentration of CEA. Patients with tumour marker level lower
than the cut-off ( ), patients with levels higher than the cut-off
(- - - -). (a) Comparison in squamous carcinoma: log-rank
P=0.91. (b) Comparison in adenocarcinoma: log-rank P=0.04.
Results
Distribution of serum and cytosolic concentration of CEA,
CA125 and SCC are depicted in Table I. Concentrations of
all three markers were far higher in cytosol than in serum;
likewise, the degree of dispersion was comparatively greater
in the cytosol-based results.
Survival
The cumulative probability of survival over 36 month follow-
up was 45%. In the univariate analysis this result was
significantly related to histological type, TNM stage and
CA125 levels in serum and cytosol (Table II). Patients with
large cell carcinoma showed significantly lower probability of
survival than patients with squamous carcinoma and
adenocarcinoma (P=0.007), but no significant differences
were detected between the latter two histological types
(P=0.642). Whereas stage Illa patients showed significantly
lower probability of survival than patients in stages I and II
(P=0.006), no differences were detected between the latter
two (P=0.799). High CA125 cytosolic levels were associated
with a significantly lower probability of survival (32% vs
60%) (P<0.001), as were high CA125 serum levels (29% vs
54%) (P=0.031). When survival estimates for histological
type and TNM stage were classified according to results of
CA125 in cytosol, patients with high levels of the marker
exhibited a significantly worse outcome (Figures 1 and 2).
Likewise, within adenocarcinoma, patients with high serum
CEA levels exhibited significantly lower survival than those
with low serum CEA (Figure 3).
Table III sets out the results of the multivariate analysis.
Shown in this table are: a first model, including the results of
cytosolic measurements after adjustment for histological type,
TNM stage and age; a second model, including serum
measurements after adjustment for the same three factors;
and a third model, including only those variables showing
significant influence in the first two models. Interaction terms
did not significantly improve any of these models. The
likelihood ratios indicate that the partial models were
significantly poorer predictors than the final combined
model. In this final model, TNM stage and histological type
proved to be the most important predictors of survival.
Cytosolic and serum levels of CA125, and serum CEA, once
adjusted for other prognostic variables, revealed themselves
to be independent predictive factors. Table III shows that the
risk of death increases in direct proportion to a rise in
cytosolic CA125, serum CA125 and serum CEA.
Recurrence
The 36 month disease-free survival rate was 47%. In the
univariate analysis, this result was related to histological type,
TNM stage, age, cytosolic CEA and serum and cytosolic
CA125 (Table IV). High CA125 cytosolic and CEA serum
levels were associated with a significantly lower probability of
disease-free survival.
Table V sets out the results of the multivariate analysis. In
the final model, TNM stage and histological type again
proved to be the most important predictors. Cytosolic CA125
and serum CEA revealed themselves to be independent
predictive factors. Table V illustrates that risk of recurrence
increases in direct proportion to a rise in cytosolic CA125
and serum CEA.
Discussion
Preoperative serum CA125, cytosolic CA125 and preopera-
tive serum CEA were observed to be closely related to
outcome figures in NSCLC. These markers provided
prognostic information not taken into account by TNM
stage or histological type. The data indicate that CA125 and
CEA levels do not simply reflect tumour load but areSerum and cytosolic CEA, CA125, SCC
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Table III Predictors of survival in non-small-cell lung cancer according to the multivariate analysis
Including only cytosolic measures Including only seric measures Final model
Variable Hazard ratio 95% CI P- Hazard ratio 95% CI P- Hazard ratio 95% CI P-
value value value
Histological type
Squamous +adenocarcinoma 1 1 1
Large-cell carcinoma 4.327 1.738-10.770 0.002 3.748 1.436-9.779 0.007 4.308 1.642-11.300 0.003
TNM stage
I-II 1 1 1
IIIA 2.448 1.327-4.516 0.004 2.304 1.253-4.238 0.007 2.609 1.398-4.870 0.003
Age
<65 1 1 1
>65 1.752 0.961-3.194 0.067 1.656 0.898-3.053 0.106 1.697 0.918-3.138 0.091
CEA in cytosol (for every Not included owing to lack of
100 ng mg-') statistical significance
CA125 in cytosol (for every 1.051 1.014-1.090 0.007 1.056 1.018-1.095 0.004
100 U mg-)
SCC in cytosol (for every 1.038 0.989-1.088 0.131 1.043 0.993-1.095 0.094
10 ng mg-')
CEA in serum (for every 1.067 1.019-1.117 0.006 1.068 1.022-1.116 0.004
10 ng ml-)
CA125 in serum (for every 1.021 1.001-1.041 0.041 1.024 1.003-1.045 0.025
10 U ml- )
SCC in serum (for every Not included owing to lack of
ng ml-1) statistical significance
Comparisonwiththe
final model
Likelihood ratio (degrees of free- 12.09 (2) 6.53 (2)
dom)
P-value 0.002 0.038
Table IV Predictors of disease-free survival in non-small-cell lung cancer according to the univariate analysis
Survival (months)
Variable No. ofpatients No. of events 12 24 36 Hazard ratio 95% CI P-value
Histological type
Squamous 71 33 74 51 51 1
Adenocarcinoma 29 12 79 52 52 0.94 0.49-1.83 0.862
Large cell 8 6 25 25 25 3.26 1.36 - 7.84 0.008
carcnoma
TNM stage
I 55 21 85 58 58 1
II 12 5 75 58 58 1.11 0.42-2.94 0.835
IIIA 41 25 51 34 34 2.28 1.27-4.08 0.006
Sex
Male 99 46 71 50 50 1
Female 9 5 78 44 44 1.04 0.41-2.62 0.935
Age
<65 65 26 75 58 58 1
65 37 25 65 36 36 1.75 1.01-3.04 0.046
CEA in cytosol
<61.1ngmg-' 54 21 80 60 60 1
61.1ngmg-' 54 30 63 39 39 1.75 1.00-3.05 0.050
CA125 in cytosol
<2OUmg-1 54 18 87 64 64 1
>20Umg-1 54 33 56 35 35 2.59 1.45-4.61 0.001
SCC in cytosol
<19ngmg 1 54 22 76 58 58 1
>l9ngmg-' 54 29 67 39 39 1.51 0.86-2.63 0.149
CEA in serum
<5ngml - 70 29 74 55 55 1
.>5ngml'- 38 22 68 38 38 1.64 0.94 -2.85 0.082
CA125 in serum
<1SUml- ' 68 28 78 57 57 1
k 15UmP-' 40 23 61 35 35 2.06 1.18-3.61 0.011
SCC in serum
<1.Sngml-1 53 27 70 47 47 1
l.5ngml- 55 24 73 51 51 0.89 0.51-1.54 0.668
95% CI, 95% confidence interval.Serum and cytosolic CEA, CA125, SCC
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Table V Predictors of disease-free survival in non-small-cell lung cancer according to the multivariate analysis
Including only cytosolic measures Including only serum measures Final model
Hazard Hazard Hazard
Variable ratio 95% CI P-value ratio 95% CI P-value ratio 95% CI P-value
Histological type
Squamous + Adenocarcinoma 1 1 I
Large Cell Carcinoma 4.468 1.824-10.950 0.001 3.417 1.361-8.576 0.009 4.344 1.709-11.040 0.002
TNM stage 1 1 1
IIIA 2.382 1.348-4.211 0.003 2.301 1.301-4.069 0.004 2.538 1.419-4.541 0.002
IIIA
Age
<65 1 1 1
>65 1.624 0.920-2.867 0.095 1.555 0.879-2.752 0.129 1.565 0.876-2.796 0.131
CEA in cytosol (for every 1.015 1.000-1.031 0.050 1.014 0.998-1.031 0.077
l00ngmg-1)
CA125 in cytosol (for every 1.053 1.016-1.091 0.005 1.056 1.018-1.095 0.003
100 Umg-')
SCC in cytosol (for every 1.039 0.997-1.083 0.068 1.041 0.998-1.086 0.062
lOngmg-1)
CEA in serum (for every 1.037 1.009-1.066 0.010 1.036 1.007-1.066 0.014
lOngm1-1)
CA125 in serum (for every 1.015 0.996-1.034 0.121 1.018 0.999-1.038 0.064
lOUml 1)
SCC in serum (for every Not included owing to lack of
ngml-1) statistical significance
Comparison with the final model
Likelihood ratio (degrees of freedom) 6.53 (2) 9.22 (3)
P-value 0.038 0.027
independent prognostic factors per se and may serve to
stratify patients within the same TNM stage and/or
histological-type risk categories. To our knowledge, this is
the first time prognostic power has ever been attributed to
quantification of cytosolic tumour markers in NSCLC.
Contrary to previous reports (Sanchez et al., 1994;
Spiridonis et al., 1995), SCC showed no prognostic
significance. We do not know the reason for the discrepancy.
The results yielded by the multivariate analysis indicate
that, for patients with serum CA125 and CEA under
10 U ml-1, and cytosolic CA125 under 100 U mg-', TNM
stage and histological type are the most important predictive
variables for both survival and recurrence. However, we have
observed that the risk of recurrence or death increases in
direct proportion to a rise in CA125 or CEA levels. Hence,
where marker concentration rises, a point will be reached
when the risk signalled by such markers may be greater than
the risk indicated by a more advanced TNM stage or more
aggressive histological type. For instance, in patients with
CEA serum levels over 140 ng ml-', the negative influence of
this marker is more important than the influence of TNM
stage. This fact underscores the need to avoid dichotomous
results (positive vs negative), at least in those cases in which
such markers are employed for estimating the prognosis. It
would seem more reasonable for these markers to be used as
continuous variables, as this would enable any predictive
information to be more efficiently exploited. Although a cut-
off point is occasionally used to define a high- or low-risk
group of patients, this approach tends to oversimplify and
even distort the relationship between variables and outcome.
Systems for anatomical tumour staging, e.g. the TNM
system, should continue as the standard patient classification
reference system. Nevertheless, by using appropriate biologi-
cal markers, groups differing in prognosis could be identified
from among patients who had undergone curative resection.
Improved staging and selection for immediate or delayed
postoperative adjuvant treatment might thereby become
possible (Murren et al., 1993). The multivariate predictive
model presented in this paper could be used to calculate post-
operative risk on a patient-by-patient basis. Using the hazard
ratios, one could estimate the risk of death or recurrence for
any patient by multiplying the ratios for all factors present.
An example of this would be a patient with stage Illa large-
cell carcinoma, having concentrations of cytosolic CA125 of
400 U mg-', serum CA125 of 40 U ml-1 and serum CEA of
40 ng ml-'. The calculated risk of such a patient dying of
lung cancer would be nearly twice that of a patient with the
same histological type and TNM stage but having the three
markers in the lowest range.
The 5 year survival rate after curative resection of NSCLC
ranges from 52% in patients with metastasis in hilar lymph
nodes to 20% in patients with metastasis in mediastinal
lymph nodes (Bains, 1991). Adjuvant therapy following
surgical resection and induction chemotherapy followed by
surgery have been proposed as the best way of improving
results after curative resection. At present, however, no clear
survival-related advantage is to be gained by such measures
(Shepherd, 1994). Inadequate selection ofpatients might have
conceivably contributed to inconclusive results. At some
future date, a score derived from a multiple-regression
approach, combining anatomical description of tumour
spread with assessment of tumour aggressiveness, may well
generate a patient-specific prognostic index (Fielding et al.,
1992). In our opinion, the possibility of individualising
patient management and, especially, of tailoring adjuvant
chemotherapy to TNM-based high-risk patients on the basis
of CEA and CA125 levels, is an attractive prospect
warranting further exploration. Patients at high risk for
recurrence and death would receive adjuvant chemotherapy.
Hypothetically, a treatment protocol could be constructed,
with patients being stratified according to a given calculated
risk vis-a-vis the overall population (Strauss et al., 1995).
However, in vitro and clinical studies would first have to
investigate the ideal chemoradiation therapy for tumours
expressing the marker.
The results of our study suggest that serum and cytosol
furnish different and mutually complementary information.
The likelihood ratios indicate that the partial models, in
which serum and cytosol were considered separately, are
significantly poorer predictors than the final combined model,
in which serum and cytosol were considered jointly. This
leads us to hypothesise that the relationship between markerSerum and cytosolic CEA, CA125, SCC
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levels in the two compartments is weak and may be
determined by factors other than the rate of production
(e.g. delivery into the bloodstream, necrosis, metabolism,
hepatic and renal excretion, production at other sites).
For a biological parameter to be used as prognostic factor
in clinical medicine, it is essential that the assay be cheap,
simple, objective, comparable, reproducible and that the
result be available in a short space of time to the doctor
(Fielding et al., 1992). In our opinion, serum and cytosolic
quantification of CEA and CA125 clearly meets these
requirements. From a theoretical standpoint, these factors
offer some advantages over other predicitive parameters.
Histological features (tumour grade, mitotic index, vascular
invasion) and immunohistochemical evaluation of oncogene-
encoded protein expression, furnish qualitative and semi-
quantitative information and are subject to a certain degree
of interobserver variation. Direct genetic studies (DNA
sequencing, polymerase chain reaction single-strand confor-
mation polymorphism), although very useful for research
purposes, are at present, unsuitable for application in daily
clinical practice. However, no accurate determination of the
practical importance of our findings can be made without
first ascertaining the exact relationship between the predictive
value of serum and cytosolic quantification of CEA and
CA125 in tandem with other factors, for assessment of
biological aggressiveness.
Serum CA125, cytosolic CA125 and serum CEA are
closely linked to outcome figures in NSCLC patients
operated on with curative intent and provide prognostic
information independent ofTNM stage and histological type.
Serum and cytosol furnish mutually complementary informa-
tion. These biomarkers enhance current ability to quantify
risk of recurrence or death on an individualised, patient-by-
patient basis.
Acknowledgements
This study was supported in part by grant 94/1556 from Spain's
Fondo de Investigaciones Sanitarias (Health Reseach Fund).
References
BAINS MS. (1991). Surgical treatment of lung cancer. Chest, 100,
826-837.
BERGMAN B, BREZICKA TF, ENGSTROM CP AND LARSSON S.
(1993). Clinical usefulness of serum assays of neuron-specific
enolase, carcinoembryonic antigen and CA50 antigen in the
diagnosis of lung cancer. Eur. J. Cancer, 29A, 198-202.
CARNEY DN. (1991). Lung cancer biology. Eur. J. Cancer, 27, 369-
372.
DIEZ M, TORRES A, POLLAN M, GOMEZ A, MAESTRO ML, ORTEGA
MD, GRANELL J, BALIBREA JL. (1994a). Prognostic significance
of serum CA125 antigen assay in non-small cell lung cancer
patients. Cancer, 73, 1368- 1376.
DIEZ M, ORTEGA MD, MAESTRO ML, TORRES A, GOMEA A,
HERNANDO F, DEL REAL A AND BALIBREA JL. (1994b).
Relationship between serum and cytosolic concentrations of
CEA, CA125 and SCC antigens in patients with non-small cell
lung cancer. J. Tumor Marker Oncol., 9, 25-30.
DIEZ M, GOMEZ A, HERNANDO F, ORTEGA MD, MAESTRO M,
MUGUERZA JM, GUTIERREZ A, GRANELL J AND BALIBREA JL.
(1995). Serum CEA, CA125 and SCC antigens and tumor
recurrence in resectable non-small cell lung cancer. Int. J. Biol.
Markers, 10, 5-10.
FIELDING LP, FENOGLIO-PREISER CM AND FREEDMAN LS.
(1992). The future of prognostic factors in outcome prediction
for patients with cancer. Cancer, 70, 2367-2377.
GAIL MH, EAGAN RT AND FELD R. (1984). Prognostic factors in
patients with resected stage I NSCLC: A report from the Lung
Cancer Study Group. Cancer, 54, 1802- 1813.
JARVISALO J, HAKAMA M, KNEKT P, STENMAN UH, LEINO A,
TEPPO L, MAATELA J AND AROMAA A. (1993). Serum tumor
markers CEA, CA50, TATI, and NSE in Lung Cancer Screening.
Cancer, 71, 1982- 1988.
LEE J AND HONG WK. (1992). Prognostic factors in lung cancer. N.
Eng. J. Med., 327, 47-48.
MOUNTAIN CF. (1986). A new international staging system for lung
cancer. Chest, 89, 225S-233S.
MURREN JR AND BUZAID AC. (1993). Chemotherapy and radiation
for the treatment ofnon-small cell lung cancer. A critical review.
Clin. Chest Med., 14, 161-171.
PICARDO A, TORRES A, MAESTRO ML, ORTEGA MD, GARCIA-
ASENJO JA, MUGUERZA JM, HERNANDO F, DIEZ M AND
BALIBREA JL. (1994). Quantitative analysis of cytosolic content
of CEA, CA125, and SCC in non-small cell lung cancer. Cancer,
73, 2305-2311.
SANCHEZ J AND MASA F, DE LA CRUZ F, DISDIER C AND
VERGARA C. (1994). Squamous Cell Carcinoma Antigen (SCC
Ag) in the diagnosis and prognosis of lung cancer. Chest, 105,
773-776.
SHEPHERD FA. (1994). Future directions in the treatment of non-
small cell lung cancer. Semin. Oncol., 21, 48-62.
SHINKAI T, SAIJO N, TOMINAGA K, EGUCHI K, SHIMIZU E,
SASAKI Y, FUJITA J, FUTAMI H, AHKURA H AND SUEMASU
K. (1986). Serial plasma carcinoembryonic antigen measurement
for monitoring patients with advanced lung cancer during
chemotherapy. Cancer, 57, 1318- 1323.
SPIRIDONIS CH, LAUFMAN LR, STYDNICK KA, NOLTIMIER JW,
CHO CL, YOUNG DL, HICKS WJ, SEGAL ML, GUY JT AND ZIDAR
BL. (1995). Decline of posttreatment tumor marker levels after
therapy ofnon-small cell lungcancer. A useful outcome predictor.
Cancer, 75, 1586- 1593.
STRAUSS GM AND SKARIN AT. (1994). Use of tumor markers in
lung cancer. Hematol./Oncol. Clin. North Am., 8, 507-532.
STRAUSS GM, KWIATKOWSKI DJ, HARPOLE DH, LYNCH TJ,
SKARIN AT AND SUGARBAKER DJ. (1995). Molecular and
pathologic markers in stage I non-small cell carcinoma of the
lung. J. Clin. Oncol., 13, 1265-1279.
WORLD HEALTH ORGANISATION (1981). Histological Typing of
Lung Tumors. World Health Organization: Geneva.